Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease

A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

(2013) Helen S. Marshall et al.   VACCINE

Potential impact of the bivalent rLP2086 vaccine onNeisseria meningitidiscarriage and invasive serogroup B disease

(2013) Annaliesa S. Anderson et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

(2012) Peter C Richmond et al.   LANCET INFECTIOUS DISEASES

The effect of iron availability on transcription of the Neisseria meningitidis fHbp gene varies among clonal complexes

(2012) H. Sanders et al.   MICROBIOLOGY-SGM

A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents

(2012) Michael D. Nissen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Molecular Epidemiology of Neisseria meningitidis Serogroup B in Brazil

(2012) Ivano de Filippis et al.   PLoS One

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial

(2012) P.C. Richmond et al.   VACCINE

A Broadly Cross-Reactive Monoclonal Antibody Against an Epitope on the N-terminus of Meningococcal fHbp

(2012) David M. Vu et al.   Scientific Reports

Bexsero

(2012) Andrew R. Gorringe et al.   Human Vaccines & Immunotherapeutics

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children

(2012) Markus Knuf et al.   Human Vaccines & Immunotherapeutics

A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults

(2012) Eric Sheldon et al.   Human Vaccines & Immunotherapeutics

Structure of the uncomplexedNeisseria meningitidisfactor H-binding protein fHbp (rLP2086)

(2011) Laura Cendron et al.   Acta Crystallographica Section F-Structural Biology and Crystallization Communications

Characterization of Neisseria meningitidis Isolates That Do Not Express the Virulence Factor and Vaccine Antigen Factor H Binding Protein

(2011) Jay Lucidarme et al.   Clinical and Vaccine Immunology

Extensive Genomic Variation within Clonal Complexes of Neisseria meningitidis

(2011) Weilong Hao et al.   Genome Biology and Evolution

Preclinical evidence for the potential of a bivalent fHBP vaccine to preventNeisseria meningitidisSerogroup C Disease

(2011) Shannon L. Harris et al.   Human vaccines & immunotherapeutics

The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans

(2011) Daniela Toneatto et al.   Human vaccines & immunotherapeutics

Enhanced Bacteremia in Human Factor H Transgenic Rats Infected by Neisseria meningitidis

(2011) David M. Vu et al.   INFECTION AND IMMUNITY

Combined Roles of Human IgG Subclass, Alternative Complement Pathway Activation, and Epitope Density in the Bactericidal Activity of Antibodies to Meningococcal Factor H Binding Protein

(2011) Serena Giuntini et al.   INFECTION AND IMMUNITY

Complement-Mediated Bactericidal Activity of Anti-Factor H Binding Protein Monoclonal Antibodies against the Meningococcus Relies upon Blocking Factor H Binding

(2011) Serena Giuntini et al.   INFECTION AND IMMUNITY

A Meningococcal Factor H Binding Protein Mutant That Eliminates Factor H Binding Enhances Protective Antibody Responses to Vaccination

(2011) P. T. Beernink et al.   JOURNAL OF IMMUNOLOGY

Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine

(2011) Jessica R. MacNeil et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Adolescent Vaccination-Coverage Levels in the United States: 2006-2009

(2011) S. Stokley et al.   PEDIATRICS

Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity

(2011) M. Scarselli et al.   Science Translational Medicine

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys

(2011) Oliver Koeberling et al.   VACCINE

Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates

(2011) Jane W. Marsh et al.   VACCINE

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States

(2011) Xin Wang et al.   VACCINE

Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen

(2011) David M. Vu et al.   VACCINE

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression

(2011) P.B. Keiser et al.   VACCINE

Meningococcal Factor H Binding Proteins in Epidemic Strains from Africa: Implications for Vaccine Development

(2011) Rolando Pajon et al.   PLoS Neglected Tropical Diseases

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

(2010) Alan Kimura et al.   Clinical and Vaccine Immunology

Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity

(2010) H. Campbell et al.   Clinical and Vaccine Immunology

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies

(2010) Kate L. Seib et al.   INFECTION AND IMMUNITY

Effect of Factor H-Binding Protein Sequence Variation on Factor H Binding and Survival ofNeisseria meningitidisin Human Blood

(2010) Kathleen Y. Dunphy et al.   INFECTION AND IMMUNITY

Meningococcal carriage by age: a systematic review and meta-analysis

(2010) Hannah Christensen et al.   LANCET INFECTIOUS DISEASES

Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease

(2010) Sonia Davila et al.   NATURE GENETICS

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection

(2010) Kate L. Seib et al.   VACCINE

A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA

(2010) Paul B. Keiser et al.   VACCINE

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

(2010) Dlawer A.A. Ala’Aldeen et al.   VACCINE

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa

(2010) Kedibone M. Mothibeli et al.   VACCINE

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1

(2010) Brunella Brunelli et al.   VACCINE

The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement

(2010) Lisa A. Lewis et al.   PLoS Pathogens

Backbone and side-chain assignment of the lipidated and non-lipidated forms of the meningococcal outer membrane protein LP2086

(2009) A. Mascioni et al.   Biomolecular NMR Assignments

Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

(2009) Amanda C. Cohn et al.   CLINICAL INFECTIOUS DISEASES

Meningococcal vaccines: a neglected topic in travel medicine?

(2009) Annelies Wilder-Smith   Expert Review of Vaccines

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs

(2009) Caroline L Trotter et al.   Expert Review of Vaccines

Functional Comparison of the Binding of Factor H Short Consensus Repeat 6 (SCR 6) to Factor H Binding Protein from Neisseria meningitidis and the Binding of Factor H SCR 18 to 20 to Neisseria gonorrhoeae Porin

(2009) J. Shaughnessy et al.   INFECTION AND IMMUNITY

Endotoxin, Capsule, and Bacterial Attachment Contribute to Neisseria meningitidis Resistance to the Human Antimicrobial Peptide LL-37

(2009) A. Jones et al.   JOURNAL OF BACTERIOLOGY

Expression of Factor H Binding Protein of Meningococcus Responds to Oxygen Limitation through a Dedicated FNR-Regulated Promoter

(2009) F. Oriente et al.   JOURNAL OF BACTERIOLOGY

Solution Structure of the Factor H-binding Protein, a Survival Factor and Protective Antigen ofNeisseria meningitidis

(2009) Francesca Cantini et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from Africa

(2009) P. T. Beernink et al.   JOURNAL OF INFECTIOUS DISEASES

Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development

(2009) Helena Lo et al.   LANCET INFECTIOUS DISEASES

The modular architecture of meningococcal factor H-binding protein

(2009) P. T. Beernink et al.   MICROBIOLOGY-SGM

Variation of the factor H-binding protein of Neisseria meningitidis

(2009) C. Brehony et al.   MICROBIOLOGY-SGM

A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups

(2009) Peter T. Beernink et al.   MOLECULAR IMMUNOLOGY

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

(2009) Muriel C. Schneider et al.   NATURE

Detecting species-site dependencies in large multiple sequence alignments

(2009) Roland Schwarz et al.   NUCLEIC ACIDS RESEARCH

Meningococcal carriage and disease—Population biology and evolution

(2009) Dominique A. Caugant et al.   VACCINE

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

(2009) Johan Holst et al.   VACCINE

Plasma fibrinogen levels after vaccination with a native outer membrane vesicle vaccine for Neisseria meningitidis

(2009) Paul B. Keiser et al.   VACCINE

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

(2009) Stefania Bambini et al.   VACCINE

Genetic polymorphisms in host response to meningococcal infection: The role of susceptibility and severity genes

(2009) Victoria Wright et al.   VACCINE

Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis

(2009) Susanne Jacobsson et al.   VACCINE

Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease

(2009) Susanne Jacobsson et al.   VACCINE

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide

(2009) Lisa K. McNeil et al.   VACCINE

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

(2009) Rolando Pajon et al.   VACCINE

Meningococcal Outer Membrane Vesicle Vaccines Derived from Mutant Strains Engineered To Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2

(2008) O. Koeberling et al.   Clinical and Vaccine Immunology

Fine Antigenic Specificity and Cooperative Bactericidal Activity of Monoclonal Antibodies Directed at the Meningococcal Vaccine Candidate Factor H-Binding Protein

(2008) P. T. Beernink et al.   INFECTION AND IMMUNITY

Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera

(2008) D. M. Granoff et al.   INFECTION AND IMMUNITY

Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37

(2008) K. L. Seib et al.   INFECTION AND IMMUNITY

Genetics and evolution of Neisseria meningitidis: Importance for the epidemiology of meningococcal disease

(2008) Dominique A. Caugant   INFECTION GENETICS AND EVOLUTION

A common gene pool for the Neisseria FetA antigen

(2008) J BENNETT et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086

(2008) Alessandro Mascioni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Complement‐Dependent Synergistic Bactericidal Activity of Antibodies against Factor H–Binding Protein, a Sparsely Distributed Meningococcal Vaccine Antigen

(2008) Jo Anne Welsch et al.   JOURNAL OF INFECTIOUS DISEASES

Epitope Mapping of a Bactericidal Monoclonal Antibody against the Factor H Binding Protein of Neisseria meningitidis

(2008) Maria Scarselli et al.   JOURNAL OF MOLECULAR BIOLOGY

Complement evasion by human pathogens

(2008) John D. Lambris et al.   NATURE REVIEWS MICROBIOLOGY

Factor H and Neisserial pathogenesis

(2008) Jo Anne Welsch et al.   VACCINE